Product acquisition from sanofi-aventis

Meda has signed an agreement with the pharmaceutical company sanofi-aventis for the acquisition of certain product rights to Imovane (Zimovane in some countries). The product is indicated for short-term treatment of insomnia. Imovane/Zimovane are well-established trademarks. Meda will make a cash payment to sanofi-aventis of EUR 10 million for the rights in Sweden, Ireland, Belgium, Greece, Luxembourg and Cyprus. For several years, Imovane/Zimovane has been sold and marketed in the territory without patent protection. The annual turnover in the acquired territory is around EUR 5 million. “This acquisition strengthens our position as a pan-European specialty pharma company”, says Anders Lonner, CEO of Meda. The European Commission has approved Meda’s acquisition of Imovane/Zimovane from sanofi-aventis

---